Ola Granström

TL;DR: Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.

TL;DR: Costs were higher than previously reported for primary care, and strongly related to hospitalization, depressive episodes, and low functioning, which suggests that effective treatment that avoids depressive episodes and hospitalization may reduce society's costs for depression.

TL;DR: The high cost of bipolar disorder is driven primarily by indirect costs, and costs were strongly associated with mood episodes, hospitalisations and low GAF scores, which suggests that treatment that reduces the risk for relapses and hospitalizations and improve functioning may decrease both the societal cost ofipolar disorder and patient suffering.

TL;DR: Differences in study design and adherence measures used across the studies were too large to allow pooling of all results, but there was a consistent trend of better adherence with less frequent dosing.

TL;DR: It is demonstrated that, over a patient's lifetime, the addition of saxagliptin to metformin is associated with improvements in quality-adjusted life years compared with SU in patients with type 2 diabetes.